New Oxford data supports UK vaccine strategy
Ever since the Oxford-AstraZeneca team announced the results of its Phase 3 trials last November, there has been a suspicion among some that their vaccine is the poor relation of the messenger RNA vaccines developed by Pfizer and Moderna. It might be cheap compared with the others, it might be easy to store and transport,
